Examines the role of BRAF mutation status on FDG uptake in recurrent papillary thyroid cancer, suggesting implications for treatment strategies.
The BRAFV600E mutation and larger tumor size are linked to increased maximum, mean, and peak FDG uptake values on [¹⁸F]FDG-PET/CT in patients with recurrent PTC. These findings improve understanding of mutation-associated metabolic behavior in recurrent PTC; however, they do not support changes in clinical management or risk stratification based solely on FDG PET/CT metrics or BRAFV600E status. Further research should investigate the potential of [¹⁸F]FDG-PET/CT metrics as biomarkers for guiding individualized treatment strategies in BRAFV600E-positive PTC.
No takes yet. Share an insight, caveat, or question.
Bastian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: